29.08.2019 MeVis Medical Solutions AG  DE000A0LBFE4

DGAP-News: MeVis Medical Solutions AG: MeVis publishes figures for the first nine months of fiscal 2018/2019


 

DGAP-News: MeVis Medical Solutions AG / Key word(s): Interim Report/9 Month figures
MeVis Medical Solutions AG: MeVis publishes figures for the first nine months of fiscal 2018/2019

29.08.2019 / 16:00
The issuer is solely responsible for the content of this announcement.


Slight increase in revenues with stable costs

  • Revenues at EUR 4.4 million approximately 12 % above previous year's level
  • EBIT of EUR 5.4 million in the first nine months (previous year: EUR 4.4 million)
  • EBIT margin increased slightly to 43 % (previous year: 37 %)
  • Profit after tax of EUR 5.8 million (previous year: EUR 5.1 million)

Bremen, August 29, 2019 - MeVis Medical Solutions AG [ISIN: DE000A0LBFE4], a leading provider of medical imaging software, announces the results for the third quarter and first nine months of fiscal year 2018/2019 (reporting period October 1, 2018 to June 30, 2019).

Revenues in the third quarter of fiscal year 2018/2019 amounted to EUR 4,350 k, about 12 % above the previous year's level (EUR 3,900 k). License business increased by 25 % in the third quarter to EUR 1,239 k (prev. year: EUR 995 k), and the maintenance business by 12 % to EUR 1,822 k (prev. year: EUR 1,632 k) compared to the previous year's period. The service business increased from EUR 1,270 k in the previous year's period to EUR 1,289 k.

Revenues in the first nine months thus amounted to EUR 12,594 k (prev. year: EUR 12,133 k) and were allocated to the segments Digital Mammography with EUR 7,135 k (prev. year: EUR 8,192 k), Development Services with EUR 3,060 k (prev. year: EUR 1,583 k) and Other Operating Activities with EUR 2,399 k (prev. year: EUR 2,358 k). With a share of 57 % (prev. year: 68 %), the Digital Mammography segment continued to be the main source of revenues.

EBIT (Earnings before financial result and taxes) amounted to EUR 5,376 k in the reporting period (prev. year: EUR 4,440 k). At 43 %, the EBIT margin improved compared with a previous year's value of 37 %.

The financial result declined significantly in the reporting period to EUR 390 k (prev. year: EUR 685 k). The change compared with the previous year is due to the development of the balance of income and expenses from exchange rate differences of EUR 494 k (prev. year: EUR 120 k) and the deterioration in the result of the 51 % share in MeVis BreastCare GmbH & Co. KG of EUR -216 k (prev. year: EUR 461 k), which is recognized at equity and interest income in the amount of EUR 127 k (prev. year: EUR 117 k).

Net profit after taxes therefore amounted to EUR 5,766 k (prev. year: EUR 5,122 k), corresponding with undiluted earnings per share of EUR 3.17 (prev. year: EUR 2.81).

************************************************************************

Contact:

Kirchhoff, Marcus / CEO


29.08.2019 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de


Language: English
Company: MeVis Medical Solutions AG
Caroline-Herschel-Str. 1
28359 Bremen
Germany
Phone: +49 421 224 95 0
Fax: +49 421 224 95 999
E-mail: [email protected]
Internet: http://www.mevis.de
ISIN: DE000A0LBFE4
WKN: A0LBFE
Listed: Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Munich, Stuttgart, Tradegate Exchange
EQS News ID: 865657

 
End of News DGAP News Service

865657  29.08.2019 

fncls.ssp?fn=show_t_gif&application_id=865657&application_name=news&site_id=boersengefluester_html


Die wichtigsten Finanzdaten auf einen Blick
  2017 2018 2019 2020 2021 2022 2023e
Umsatzerlöse1 18,54 16,76 18,07 17,13 16,21 18,76 17,34
EBITDA1,2 9,18 7,60 8,25 5,97 4,77 7,99 3,99
EBITDA-Marge3 49,51 45,35 45,66 34,85 29,43 42,59
EBIT1,4 7,96 6,69 8,00 5,81 4,64 7,90 3,89
EBIT-Marge5 42,93 39,92 44,27 33,92 28,62 42,11 22,43
Jahresüberschuss1 5,62 7,17 8,07 5,70 4,55 7,79 4,92
Netto-Marge6 30,31 42,78 44,66 33,27 28,07 41,52 28,37
Cashflow1,7 7,32 5,52 6,55 2,89 9,13 4,86 5,85
Ergebnis je Aktie8 3,09 3,94 4,43 3,13 2,50 4,28 2,70
Dividende8 0,95 0,95 0,95 0,95 0,95 0,95 0,95
Quelle: boersengefluester.de und Firmenangaben

  Geschäftsbericht 2023 - Kostenfrei herunterladen.  
1 in Mio. Euro; 2 EBITDA = Ergebnis vor Zinsen, Steuern und Abschreibungen; 3 EBITDA in Relation zum Umsatz; 4 EBIT = Ergebnis vor Zinsen und Steuern; 5 EBIT in Relation zum Umsatz; 6 Jahresüberschuss (-fehlbetrag) in Relation zum Umsatz; 7 Cashflow aus der gewöhnlichen Geschäftstätigkeit; 8 in Euro; Quelle: boersengefluester.de

Wirtschaftsprüfer: Deloitte

INVESTOR-INFORMATIONEN
©boersengefluester.de
MeVis Med. Solutions
WKN Kurs in € Einschätzung Börsenwert in Mio. €
A0LBFE 25,000 Halten 45,50
KGV 2025e KGV 10Y-Ø BGFL-Ratio Shiller-KGV
10,42 10,26 1,02 7,62
KBV KCV KUV EV/EBITDA
2,55 7,77 2,62 10,61
Dividende '22 in € Dividende '23e in € Div.-Rendite '23e
in %
Hauptversammlung
0,95 0,95 3,80 19.03.2024
Q1-Zahlen Q2-Zahlen Q3-Zahlen Bilanz-PK
- 27.05.2024 - 29.01.2024
Abstand 60Tage-Linie Abstand 200Tage-Linie Performance YtD Performance 52 Wochen
0,33% -8,38% -0,79% -30,17%
    
Weitere Ad-hoc und Unternehmensrelevante Mitteilungen zu MeVis Medical Solutions AG  ISIN: DE000A0LBFE4 können Sie bei EQS abrufen


Medtech , A0LBFE , M3V , XETR:M3V